1. Home
  2. MDV vs ELTX Comparison

MDV vs ELTX Comparison

Compare MDV & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modiv Industrial Inc. Class C

MDV

Modiv Industrial Inc. Class C

HOLD

Current Price

$18.00

Market Cap

187.5M

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

BUY

Current Price

$4.11

Market Cap

185.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
MDV
ELTX
Founded
2015
2011
Country
United States
United States
Employees
9
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.5M
185.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MDV
ELTX
Price
$18.00
$4.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$18.00
$18.00
AVG Volume (30 Days)
55.5K
3.3M
Earning Date
05-08-2026
05-12-2026
Dividend Yield
7.50%
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.80
$2.66
52 Week High
$18.83
$16.00

Technical Indicators

Market Signals
Indicator
MDV
ELTX
Relative Strength Index (RSI) 50.81 32.85
Support Level $17.60 N/A
Resistance Level $18.75 $9.95
Average True Range (ATR) 0.37 1.52
MACD -0.13 -1.04
Stochastic Oscillator 30.33 10.79

Price Performance

Historical Comparison
MDV
ELTX

About MDV Modiv Industrial Inc. Class C

Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in, and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from the company's consolidated real estate properties.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: